---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-302580"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2026-07-14T12:11:11+00:00"
generated_at: "2026-07-14T12:15:07.754904+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inhibikase raises $50M through ATM sale of 25M shares to RA Capital for PAH study

## Summary
- Sold 25,000,000 shares to RA Capital Management for $50M gross proceeds via ATM facility.
- Proceeds will fund operations through topline data readout from Phase 3 IMPROVE-PAH Part B.
- Shares sold under effective shelf registration (Form S-3) and ATM prospectus supplement.
- Company is clinical-stage developing IKT-001 for Pulmonary Arterial Hypertension.

## SEC filing metadata
- accession: 0001193125-26-302580
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2026-07-14T12:11:11+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312526302580/0001193125-26-302580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312526302580/d157026d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-302580
- JSON: https://secwatch.observer/filing/0001193125-26-302580.json
- Plain text: https://secwatch.observer/filing/0001193125-26-302580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.